iclaprim   Click here for help

GtoPdb Ligand ID: 10820

Synonyms: AR-100 | AR100 | Mersarex® | RO-48-2622 | RO-482622
Compound class: Synthetic organic
Comment: Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that reduces folic acid synthesis. It is a diaminopyrimidine antibacterial that has broad-spectrum activity against Gram +ve pathogens [1]. Iclaprim is a racemic mixture of stereoisomers. We show the 'flat' structure to represent the mixture.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 105.51
Molecular weight 354.17
XLogP 1.91
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(Cc2cnc(nc2N)N)c2c(c1OC)OC(C=C2)C1CC1
Isomeric SMILES COc1cc(Cc2cnc(nc2N)N)c2c(c1OC)OC(C=C2)C1CC1
InChI InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)
InChI Key HWJPWWYTGBZDEG-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Iclaprim was developed to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired bacterial pneumonia[4]. Phase 3 trials comparing iclaprim against both vancomycin and linezolid for ABSSSI have been completed. An application for marketing authorisation to the EMA for Mersarex, to be used to treat complicated skin and soft tissue infections, was withdrawn in 2009 [3]. A New Drug Application (from Motif Bio) for treatment of ABSSSI was accepted for review by the FDA in 2018. The FDA's response to this NDA stipulated that more data, and additional clinical study, addressing liver toxicity risk would be required before it could be approved [2].